Fig. 2.

Comprehensive characterization of the ZL12138L vaccine construct: design strategy, amino acid composition, solubility profile, and global population coverage. (A) The ZL12138L vaccine construct integrates multiple immunostimulatory components, including the TLR-2 agonist EAST-6, the pan-DR T helper epitope PADRE, 12 HTL epitopes, 13 CTL epitopes, 8 B-cell epitopes, and the TLR-4 agonist RS-09, to enhance immunogenicity. (B) The primary sequence of ZL12138L is depicted with the distinct immunological elements highlighted in different colors to facilitate the visual identification of each component. (C) Solubility assessment using the Protein-Sol server revealed a calculated solubility score exceeding 0.45, indicative of favorable solubility properties. (D) The secondary structure of ZL12138L was predicted using the PSIPRED server. The structural elements, α-helices (pink), β-strands (yellow), and coils (gray), provide a detailed view of the conformational landscape. (E) Global demographic analysis of HLA allele coverage by the ZL12138L vaccine.

Abbreviations: HLA, human leukocyte antigen.